JNJ · Johnson & Johnson

The thesis

Johnson & Johnson's drug pipeline keeps producing approvals and positive trials, but weak medical devices and $1.36 per share of guided 2027 deal dilution make the shares more likely to lag the S&P 500 over the next three months. The Enterprise Business Review on 8 December 2026 and the fourth-quarter report expected in late January 2027 decide whether earnings grow in 2027.

The rating is Low because the price already sits above analysts' targets while the two numbers behind the caution are unchanged. MedTech grew 2.5% operationally in the third quarter, and management guided on 13 October 2026 to $1.36 per share of 2027 dilution from the Firefly Bio acquisition and the Sail Biomedicines collaboration, against $0.64 in 2026.

The shares closed at $283.52 on 12 November 2026, above the $279.41 average analyst target Yahoo Finance listed on 10 November 2026 and the $275.92 consensus target MarketBeat reported on 9 November 2026. The market has priced in the drug launches and a clean 2027; further gains depend on what management says about 2027 earnings on 8 December 2026.

Bullish and bearish views on Johnson & Johnson

The bull case on Johnson & Johnson (JNJ), in brief: Drug growth accelerated despite Stelara. The bear case: medical devices missed again.

Bull case

• Drug growth accelerated despite Stelara. Innovative Medicine sales rose 7.9% operationally to $16.757 billion in the third quarter, according to the 13 October 2026 release. That beat the second quarter's 6.8% while biosimilar competition to Stelara cut growth by about 6.9 percentage points.
• Launch drugs keep compounding. On the 13 October 2026 call the company reported operational growth of 68.2% for Tremfya, 15.6% for Darzalex and 35.2% for Carvykti.
• Rybrevant reaches beyond lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval to subcutaneous Rybrevant Faspro on 5 November 2026 for recurrent or metastatic head and neck squamous cell carcinoma, CURE reported on 6 November 2026. The approval rests on a 42% overall response rate in the Phase 1b/2 OrigAMI-4 trial.
• Icotyde is widening its label. Johnson & Johnson reported positive Phase 3 ICONIC-PsA 1 results for oral Icotyde (icotrokinra) in psoriatic arthritis on 7 November 2026. In patients with qualifying skin disease, 57% reached clear or almost clear skin against 14% on placebo, Benzinga reported on 9 November 2026.
• Caplyta has a second mania win. The company said on 10 November 2026 that a second pivotal Phase 3 study of Caplyta (lumateperone) in bipolar I mania met its primary and key secondary endpoints. The first study read out positive on 21 September 2026, giving two trials to support a filing in a use where the drug is not yet approved.
• Early prostate cancer data look clean. The company reported on 8 November 2026 that the pasritamig and JNJ-9401 combination produced a 73% prostate-specific antigen response with no grade 3 or higher treatment-related adverse events in a Phase 1 study, Benzinga reported on 9 November 2026.
• 2026 outlook raised again. The company guides to $101.0 billion to $101.4 billion of sales and adjusted earnings per share (EPS) of $11.05–11.15, up from $100.8 billion to $101.4 billion and $10.96–11.11 before the 13 October 2026 report.

Bear case

• Medical devices missed again. MedTech grew 2.5% operationally to $8.642 billion in the third quarter, with international sales up 0.1%, according to the 13 October 2026 release. MedTech head Tim Schmid said on the call that results were "below expectations previously communicated."
• 2027 earnings carry heavy dilution. The $1.36 per share of guided 2027 dilution is more than double the 2026 figure. Third-quarter adjusted EPS of $2.59 was already down 7.5% from a year earlier.
• Talc verdicts keep coming. An Alameda County, California jury awarded $34.21 million in a mesothelioma case on 9 November 2026, finding Johnson & Johnson 40% liable, Law.com reported. These asbestos claims sit outside the $5.5 billion ovarian settlement; on 12 November 2026 the company sent the FDA a letter proposing a definition of asbestos in consumer talc and supporting yearly testing, Mealey's reported.
• The ovarian settlement is still conditional. The $5.5 billion proposal from 28 July 2026 covers about 76,000 claims and takes effect only if at least 95% of claimants join, according to AP. The company has published no participation count.
• Orthopaedics exit lost its deal route. Talks to combine DePuy Synthes with Smith & Nephew collapsed over the chief executive role, the Financial Times and Reuters reported on 23 October 2026. The company still targets a separation by mid-2027.
• The price is above the targets. The 12 November 2026 close of $283.52 sits above the $279.41 average target on Yahoo Finance and above Leerink Partners' $272 target, reaffirmed on 28 October 2026.
• Senior executives sold shares this year. Chief executive Joaquin Duato exercised options and sold 123,291 shares at an average $261.17 on 13 August 2026, Innovative Medicine head Jennifer Taubert sold 15,000 shares at $263.36 on 17 August 2026, and MedTech head Tim Schmid sold 33,597 shares at $274.74 on 2 September 2026, according to SEC Form 4 filings.

Price setup

The shares closed at $283.52 on 12 November 2026 and set a 52-week intraday high of $286.08 in that session. The last close is 0.9% below that high. The 3-month change is 9.4%, measured from the 14 August 2026 close.

The pipeline run from 5 November to 10 November 2026 moved the shares from a $272.32 close on 5 November 2026 to $282.11 on 9 November 2026, then $280.78 and $280.41 on the next two sessions, before the 12 November 2026 high. As of the 12 November 2026 close the 50-day moving average stands at $266.72 and the 200-day at $248.00, both well under the price.

The 52-week closing low was $194.39 on 12 November 2025, so the shares have rerated sharply over the year. The level the case now turns on is the 12 November 2026 high: holding below it into the 8 December 2026 review would fit a lag call, while a sustained move through it would mean investors are paying ahead of the 2027 numbers.

Catalysts ahead

• 19 November 2026: Deadline for talc plaintiffs in federal litigation to show why cases should not be dismissed for lack of admissible causation evidence. The plaintiffs' response bears on the pressure to join the $5.5 billion settlement and its 95% participation condition.
• 8 December 2026: Enterprise Business Review for investors, with segment, pipeline and long-term strategy presentations. First detailed look at how management plans to absorb $1.36 per share of 2027 deal dilution and restart MedTech growth; 2027 EPS commentary above $11.10 would undercut the lag call.
• ~15 December 2026 (est.): European Commission decision on the Talvey multiple myeloma indication extension. Approval would widen the European label for one of the oncology launches that drive drug growth.
• ~26 January 2027 (est.): Fourth-quarter 2026 results and formal 2027 guidance. Shows whether MedTech growth recovers from 2.5% and whether 2027 adjusted EPS guidance clears the 2026 midpoint of $11.10.
• ~30 June 2027 (est.): DePuy Synthes orthopaedics separation, targeted by mid-2027. With the Smith & Nephew talks reported collapsed on 23 October 2026, a spin-off is the stated path for removing the slower orthopaedics business.

What would change the view

A weekly close above $290, over the 12 November 2026 intraday high of $286.08 and above every cited consensus target, which would show the shares leading; or 2027 adjusted EPS guidance above the 2026 midpoint of $11.10.

What it trades with

Johnson & Johnson trades with large-cap pharmaceutical and health-care stocks and with defensive sectors; on 11 November 2026, when Benzinga reported cyclicals leading and defensives trailing, the shares closed at $280.41, slightly lower. Talc litigation is a company-specific driver that can move the shares apart from peers. Halozyme supplies the ENHANZE technology in Rybrevant Faspro, per Contract Pharma on 6 November 2026, and Protagonist Therapeutics partners on Icotyde, so news on those drugs reaches both companies. Smith & Nephew and other orthopaedics makers move on news about the DePuy Synthes separation.